Talk:New Article Requests

Before You Submit a Proposal

GENERAL GUIDELINES: Your proposal should be concise, accurate, and well written. It will be reviewed by EyeWiki editors, who are practicing ophthalmologists. Spelling, grammar, and punctuation matter — your proposal reflects the quality you will bring to EyeWiki as a contributor.
- The EyeWiki policy on AI use applies to new article proposals as well as to published content. AI tools may be used solely to improve the readability and language of your work. They may not be used to replace essential research or writing tasks, including ideation, literature review, or drafting.
EVALUATION CRITERIA: Review these to be sure your proposal is eligible. The current acceptance rate for new articles is approximately 41%-43%.
EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be included in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
- If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
- Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics. If there is substantial new evidence that has to come to light since the last proposal was rejected, you may resubmit a topic citing the new evidence to support a stand-alone EyeWiki article.
PREAPPROVED TOPICS and ARTICLES NEEDING REVISION: Can't think of a topic for a new article? Consider revising topics on this list of articles flagged by the editorial board for revisions. Visit the discussion pages of these articles to find out what is needed. No approval is necessary to revise these articles. Currently, there are some new suggested topics that have been preapproved for stand-alone articles. Contact eyewiki@aao.org if you would like to work on one of the pre-approved new articles and can complete it within 30 days.

Instructions

IMPORTANT: Review the section above "Before You Submit a Proposal"
Click the "Add topic" link to create a new proposal on this page not in your own talk page.
Then add the relevant list items as shown
- Title: Enter this in the Subject field
- Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article. Very rarely EyeWiki editors may request additional information beyond your proposal; in most cases this is not necessary.
- Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
- Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
  - SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
Click: SAVE at the bottom of the page

Sample Proposal

Biosimilars in Ophthalmology
Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)

Per- and Polyfluoroalkyl Substances (PFAS) in Ophthalmologic Disease

Summary: Per- and polyfluoroalkyl substances (PFAS), commonly referred to as “forever chemicals,” are persistent environmental pollutants increasingly linked to systemic and ocular disease. Emerging epidemiologic and mechanistic evidence suggests associations between PFAS exposure and multiple ophthalmologic conditions, including age-related macular degeneration (AMD), cataracts, vitreous disorders, visual impairment, and developmental myopia. Proposed mechanisms include oxidative stress, chronic inflammation, lipid dysregulation, extracellular matrix remodeling, and hormonal disruption affecting ocular growth and aging. This article will provide EyeWiki readers information regarding the current literature of PFAS-associated ocular disease and provide an overview of the biologic mechanisms underlying these associations. Additionally, this article will discuss clinical implications, public health considerations, patient counseling strategies for PFAS exposure reduction, and future research directions regarding the role of PFAS in opthalmology. Section: Miscellaneous Submitted by: Safa.Ibrahim (talk) 21:41, May 18, 2026 (PDT)

Nitrosative Stress in Ophthalmology

Summary: Nitrosative stress results from excessive production of reactive nitrogen species (RNS), including nitric oxide and peroxynitrite. Nitrosative stress can disrupt cellular signaling and induce oxidative protein modification, mitochondrial dysfunction, and general inflammation. Although nitric oxide plays essential roles in ocular function, dysregulated nitric oxide metabolism may be implicated in the pathogenesis of major ophthalmologic diseases. Emerging evidence links nitrosative stress to age-related macular degeneration, diabetic retinopathy, glaucoma, keratopathy, and cataract formation. This article will provide EyeWiki readers a summary of the current literature regarding the mechanisms, ocular complications, and biomarkers, such as 3-nitrotyrosine, of nitrosative stress in ophthalmology. This article will also discuss management strategies for nitrosative stress, including nitric oxide-modulating drugs, antioxidant therapy, and tyrosine kinase inhibitors. Section: Miscellaneous Submitted by: Safa.Ibrahim (talk) 21:43, May 18, 2026 (PDT)

Iris nevus

Summary: Iris nevus is the most common melanocytic lesion of the iris that may present as a circumscribed pigmented or non-pigmented lesion. Although typically stable and asymptomatic, iris nevi are clinically important because a subset may demonstrate growth and malignant transformation into iris melanoma. This article will review the epidemiology, clinical presentation, imaging characteristics, differential diagnosis, and risk factors associated with iris nevus progression, including established predictive features such as documented growth, ectropion uveae, hyphema, inferior location, and angle involvement, including the ABCDEF guide. The article will also discuss diagnostic approaches using slit-lamp biomicroscopy, anterior segment OCT, ultrasound biomicroscopy, and gonioscopy, as well as current recommendations for monitoring, follow-up intervals, and indications for referral or treatment. In addition, the article will summarize distinguishing features between iris nevus and other iris lesions, including iris melanoma, iris freckles, cysts, and inflammatory or metastatic lesions.
Section: Oncology/Pathology
Submitted by: Vasco.M.Lobo (talk) 10:54, May 21, 2026 (PDT)